Adelaide-based health-tech firm splose has secured USD$32 million in a landmark Series A funding round, the largest ever for a South Australian-founded software company. The investment was led by US growth equity firm Spectrum Equity, with participation from Athletic Ventures. This significant capital injection is set to accelerate the company's mission to streamline operations for Allied Health professionals globally.
Addressing a Sector in Need
Founded in 2018 by Nicholas Sanderson, splose was born from the observation that practitioners were overwhelmed by administrative duties. Legacy software systems created inefficiencies, forcing clinicians to spend valuable time on manual data entry and payment reconciliation. This administrative burden directly impacted their ability to focus on delivering high-quality patient care, a core problem the company aimed to solve.
An AI-Powered Solution
The splose platform serves as a comprehensive, end-to-end operating system for Allied Health practices, including physiotherapists and occupational therapists. It consolidates critical functions such as appointment scheduling, client management, invoicing, and compliance into a single, user-friendly interface. This integrated approach has made it the preferred software for over 20,000 practitioners across Australia, the UK, and New Zealand.
A key differentiator for the platform is its deep integration of artificial intelligence, which was introduced in late 2024. Features like an AI scribe for transcribing sessions and tools for summarizing client histories automate time-consuming tasks. The company reports that these AI capabilities enable practitioners to complete clinical notes up to four times faster than manual methods.
Fueling Global Expansion and Innovation
The new capital will be strategically deployed to fuel the company's next phase of growth and product enhancement. Key priorities include accelerating product development with a focus on deeper AI integration and improving integrated payment solutions. The funding will also support the expansion of its teams in Adelaide, Sydney, Melbourne, and London to drive innovation faster.
A significant portion of the investment is earmarked for aggressive expansion into the United Kingdom, a market where splose has already seen over 300% growth. This international push builds on the company's impressive traction, having doubled its user base in the last twelve months. The focus remains on building the best possible solution for the Allied Health community worldwide.
Strategic Partnerships and Investor Confidence
Lead investor Spectrum Equity was drawn to splose's strong position in a specialized vertical and its dedicated user base. Matt Neidlinger, a Partner at the firm who will join the splose board, noted that the platform is "truly loved by its users." He emphasized the company's success in helping clinicians run more efficient and scalable practices through its innovative use of AI.
The round also saw participation from Athletic Ventures, a fund backed by elite athletes who recognize the synergy between sports and health. Co-founder Matt Dellavedova highlighted the platform's ability to solve real-world problems for clinicians. Continued support comes from early-stage investor EVP, which praised the team's progress and welcomed the new partners for the company's next chapter.
This historic $32 million funding round marks a pivotal moment for splose, validating its vision and solidifying its role as a leader in health technology. By empowering practitioners with advanced AI tools and a streamlined platform, the company is not only enhancing business efficiency but also fundamentally improving the delivery of patient care. The investment positions splose for significant global impact, promising a new era of innovation for the Allied Health sector.